Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

NCT ID: NCT01746420

Last Updated: 2019-07-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-12-12
• Study Completion Date: 2014-10-21

Brief Summary

The purpose of this study is to determine whether recombinant human platelet-derived growth factor (rhPDGF-BB) Injection is effective in the treatment of lateral epicondylitis (tennis elbow).

Detailed Description

Methodology: Randomized, single ascending dose, double-blinded, placebo controlled, multi-center study

Study Center(s): 6

Number of Subjects: 100

Diagnosis and Main Inclusion Criteria: Lateral epicondylitis; male and female subjects 21 -80 years of age

Study Drug, Dose, Regimen:

Dose A: sodium acetate buffer alone - placebo control Dose B: sodium acetate buffer + 0.45 mg rhPDGF-BB Dose C: sodium acetate buffer + 0.75 mg rhPDGF-BB Dose D: sodium acetate buffer + 1.5 mg rhPDGF-BB Dose E: sodium acetate buffer + 3.0 mg rhPDGF-BB

Duration and Route of Administration: Single administration dose by injection into the extensor carpi radialis brevis (ECRB)

Duration of Follow-up: 24 weeks (6 months) post-operative follow-up

Conditions

Lateral Epicondylitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Placebo Control

Dose A - sodium acetate buffer (0 mg rhPDGF-BB)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

sodium acetate buffer (0 mg rhPDGF-BB)

0.45 mg rhPDGF-BB

Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB

Group Type: EXPERIMENTAL

rhPDGF-BB Injection

Intervention Type: DRUG

Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

0.75 mg rhPDGF-BB

Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB

Group Type: EXPERIMENTAL

rhPDGF-BB Injection

Intervention Type: DRUG

Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

1.5 mg rhPDGF-BB

Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB

Group Type: EXPERIMENTAL

rhPDGF-BB Injection

Intervention Type: DRUG

Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

3.0 mg rhPDGF-BB

Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB

Group Type: EXPERIMENTAL

rhPDGF-BB Injection

Intervention Type: DRUG

Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

Interventions

rhPDGF-BB Injection

Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

Intervention Type: DRUG

Placebo

sodium acetate buffer (0 mg rhPDGF-BB)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subject has signed the Institutional Review Board (IRB) approved Informed Consent Form specific to this study prior to enrollment

2. Subject has a clinical diagnosis of lateral epicondylitis

3. Subject's symptoms can be reproduced with resisted supination or wrist dorsiflexion

4. Subject's symptoms have persisted for at least 3 months despite conservative treatment that includes one or combinations of:

1. Physical therapy

2. Splinting

3. Nonsteroidal antiinflammatory drug (NSAID)

4. Corticosteroid injection

5. Subject is independent, ambulatory, and can comply with all post-injection evaluations and visits

6. Subject is 21-80 years of age and considered to be skeletally mature

Exclusion Criteria

1. Subject has undergone previous corticosteroid injection therapy to the effected elbow in less than three months prior to enrollment

2. Subject has received previous Platelet Rich Plasma (PRP) injection to the affected elbow

3. Subject is deemed to require a corticosteroid injection into the affected elbow during the course of the study

4. Subject uses chronic medications known to affect the skeleton (e.g. glucocorticoid usage >10mg/day)

5. Subject has undergone surgical intervention to the affected elbow for the treatment of lateral epicondylitis

6. Subject has a positive medical history of any of the following:

1. medial epicondylitis

2. radial tunnel syndrome

3. carpal tunnel syndrome

4. septic or gouty arthritis

5. cervical radiculopathy

6. trauma to the affected elbow within the past 6 weeks

7. neuromuscular or musculoskeletal deficiency, which limits the ability to perform functional measurement (e.g. grip strength test)

7. Subject currently has an acute infection at the injection site

8. Subject has tested positive or been treated for a malignancy in the past or is suspected of having a malignancy or are currently undergoing radio- or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed rhPDGF-BB Injection treatment site

9. Subject is physically or mentally compromised (e.g. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant

10. Subject has an allergy to yeast-derived products

11. Subject has received an investigational therapy or approved therapy for investigational use within 30 days of injection procedure or during the follow-up phase of this study

12. Subject is a prisoner, or is known or suspected to be transient

13. Subject's condition represents a worker's compensation case

14. Subject is currently involved in a health-related litigation procedure

15. Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within the 12 months prior to screening for study entry

16. Subject is pregnant, or able to become pregnant but not practicing a medically-accepted form of birth control, and/or intending to become pregnant during this study period

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BioMimetic Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Edward Akelman, MD

Role: PRINCIPAL_INVESTIGATOR

Brown University

Locations

Arizona Research Center

Phoenix, Arizona, United States

Tucson Orthopaedic Institute

Tucson, Arizona, United States

NEA Baptist Clinic

Jonesboro, Arkansas, United States

Coastal Orthopedics & Sports Medicine

Bradenton, Florida, United States

Foundation for Orthopaedic Research and Education

Tampa, Florida, United States

OrthoCarolina

Charlotte, North Carolina, United States

Countries

United States

Other Identifiers

BMTI-2010-02

Identifier Type: -

Identifier Source: org_study_id